What is Angioslide?
Angioslide is a privately-held medical technology firm dedicated to enhancing patient outcomes during vascular interventions. The company specializes in the development and marketing of the PROTEUS device family, which remains the only FDA-cleared solution designed to capture and remove embolic particles directly at the lesion site in peripheral arteries. By focusing on cost-effective and innovative emboli management, Angioslide occupies a critical niche in the cardiovascular and peripheral vascular market, providing physicians with tools that mitigate the risks associated with plaque dislodgement during angioplasty and stenting procedures.
How much funding has Angioslide raised?
Angioslide has raised a total of $24.9M across 3 funding rounds:
Series A
$4M
Series B
$14.6M
Series C
$6.3M
Series A (2006): $4M with participation from Viola Partners
Series B (2013): $14.6M led by Ofer-Hi Tech, Triventures, and Agate Medical investments
Series C (2013): $6.3M supported by Viola Partners and TriVentures
Key Investors in Angioslide
Viola Partners
Viola Group is Israel's leading technology investment group, managing over $6 billion in assets. The firm supports Israeli entrepreneurs in building transformational technology companies through its multi-strategy investment approach.
TriVentures
Triventures is a global venture capital fund that invests in early-stage companies with innovative breakthroughs in healthcare and other industries, focusing on bio-convergence and data-driven technologies.
Agate Medical investments
Agate Medical Investments is a specialized venture firm focused on identifying and backing high-potential medical device and healthcare technology companies.
What's next for Angioslide?
Following the recent major strategic investment, Angioslide is positioned to scale its commercial operations and potentially expand the clinical applications of the PROTEUS platform. The company's focus remains on solidifying its market presence in the peripheral vascular space while leveraging its existing intellectual property to drive further innovation in embolic protection. As the firm moves beyond its Series C stage, the strategic priority will likely shift toward broader market penetration and the pursuit of long-term clinical data to support the adoption of its technology as a standard of care in vascular surgery. The continued support from seasoned healthcare investors suggests a robust roadmap for future growth and potential exit opportunities within the medical device landscape.
See full Angioslide company page
